Intellia Therapeutics’ (NTLA) Buy Rating Reaffirmed at Canaccord Genuity Group
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Canaccord Genuity Group in a research note issued on Tuesday,Benzinga reports. They presently have a $90.00 price target on the stock. A number of other research analysts have also recently commented on NTLA. The Goldman Sachs Group reduced […]
More Stories
Court Blocks Subpoenas Tied to Criminal Probe of Fed Chair Jerome Powell
By Andrew Moran A federal judge blocked subpoenas issued to the Federal Reserve as part of a criminal investigation of...
Jeffrey Epstein Guard Called to Testify Before House Oversight Committee
By Jacki Thrapp One of the guards on duty when Jeffrey Epstein died in his cell will testify before the...
Senate Floor Fight Reveals How Far Apart Democrats and Republicans Are on DHS Shutdown
By Chase Smith For two days this week, senators took turns proposing ways to end the partial shutdown of the...
US Mortgage Rates Jump to 6.11 Percent
By Naveen Athrappully Mortgage rates have risen for the second consecutive week, moving up to 6.11 percent after briefly dipping...
US Sending More Marines, Warships to Middle East
By Ryan Morgan ARLINGTON, Va.—A U.S. Marine Expeditionary Unit is set to reposition to the Middle East amid ongoing military...
How the US Can Adjust to Middle East Oil Disruptions
By Kevin Stocklin The U.S.–Israeli war with Iran has brought heightened volatility to energy and equity markets, with the price...